CIK 0000855654
IMGN ImmunoGen, Inc.
Insider trading from SEC Form 4. Last filing Feb 12, 2024.
In brief
ImmunoGen, Inc. (IMGN) has 53 SEC Form 4 filings on file from 16 insiders, the latest filed on Feb 12, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
15 open-market trades have been scored at IMGN. The newest: Stacy Ann Coen (SVP & CHIEF BUSINESS OFFICER) sold $134k of stock on Feb 5, 2024, filed Feb 6, 2024, scored 6 (weak), under a 10b5-1 plan. The largest of the 15 shown: Theresa Wingrove (SVP OF REGULATORY AFFAIRS) sold $5.6M on Jan 16, 2024, scored 25 (weak), under a 10b5-1 plan. 4 insiders sold within 14 days of each other around Feb 5, 2024.
20 Form 144 notices of planned sales are on file, the latest filed Feb 5, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
16
with a Form 4 at this company
Signals
Open-market buys and sells at ImmunoGen, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 6Weak | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER sell | $134k 4,583 shares | -6% | - | |
| 24Weak | Mark J Enyedy CHIEF EXECUTIVE OFFICER sell | $589k 20,107 shares | -3% | - | |
| 8Weak | Renee Lentini VP & PRIN ACCTG OFFICER sell | $77k 2,631 shares | -15% | - | |
| 20Weak | Theresa Wingrove SVP OF REGULATORY AFFAIRS sell | $352k 12,027 shares | -36% | - | |
| 25Weak | Theresa Wingrove SVP OF REGULATORY AFFAIRS sell | $5.6M 187,667 shares | -98% | - | |
| 10Weak | Renee Lentini VP & PRIN ACCTG OFFICER sell | $195k 6,548 shares | -44% | - | |
| 33Weak | Theresa Wingrove SVP OF REGULATORY AFFAIRS sell | $3.5M 117,445 shares | -98% | - | |
| 25Weak | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER sell | $112k 3,826 shares | -10% | - | |
| 34Weak | Kristine Peterson director sell | $578k 20,000 shares | -100% | - | |
| 40Moderate | Theresa Wingrove SVP OF REGULATORY AFFAIRS sell | $4.9M 171,216 shares | -1783% | - | |
| 40Moderate | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER sell | $1.7M 108,609 shares | -172% | - | |
| 40Moderate | Theresa Wingrove SVP OF REGULATORY AFFAIRS sell | $2.6M 166,725 shares | -98% | - | |
| 60Notable | Renee Lentini VP & PRIN ACCTG OFFICER sell | $3.4M 219,545 shares | -100% | - | |
| 30Weak | Theresa Wingrove SVP OF REGULATORY AFFAIRS sell | $325k 19,517 shares | -87% | - | |
| 45Moderate | Theresa Wingrove SVP OF REGULATORY AFFAIRS sell | $2.8M 192,004 shares | -99% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 5, 2024 | Coen Stacy Ann Officer | 4,583 0.00% of outstanding | $134k | Feb 5, 2024 | $1.9M |
| Feb 5, 2024 | Enyedy Mark J Officer, Director | 20,107 0.01% of outstanding | $589k | Feb 5, 2024 | none |
| Feb 5, 2024 | Lentini Renee Officer | 2,631 0.00% of outstanding | $77k | Feb 5, 2024 | $3.6M |
| Feb 5, 2024 | Wingrove Theresa Officer | 12,027 0.00% of outstanding | $352k | Feb 5, 2024 | $23M |
| Jan 16, 2024 | Wingrove Theresa Officer | 187,667 0.07% of outstanding | $5.6M | Jan 16, 2024 | $14M |
| Dec 26, 2023 | Lentini Renee Officer | 6,548 0.00% of outstanding | $195k | Dec 26, 2023 | $3.4M |
| Dec 15, 2023 | Wingrove Theresa Officer | 117,445 0.04% of outstanding | $3.5M | Dec 15, 2023 | $14M |
| Dec 1, 2023 | Coen Stacy Ann Officer | 3,826 0.00% of outstanding | $112k | Nov 30, 2023 | $1.7M |
| Nov 30, 2023 | Wingrove Theresa Officer | 164,424 0.06% of outstanding | $4.8M | Nov 30, 2023 | $8.8M |
| Nov 30, 2023 | Peterson Kristine Director | 20,000 0.01% of outstanding | $578k | Nov 30, 2023 | $161k |
| Nov 29, 2023 | Wingrove Theresa Officer | 6,792 0.00% of outstanding | $113k | Nov 29, 2023 | $8.7M |
| Nov 17, 2023 | Coen Stacy Ann Officer | 78,223 0.03% of outstanding | $1.3M | Nov 17, 2023 | $487k |
| Nov 16, 2023 | Coen Stacy Ann Officer | 4,100 0.00% of outstanding | $66k | Nov 16, 2023 | $421k |
| Nov 15, 2023 | Coen Stacy Ann Officer | 26,286 0.01% of outstanding | $421k | Nov 15, 2023 | none |
| Nov 15, 2023 | Wingrove Theresa Officer | 166,725 0.06% of outstanding | $2.6M | Nov 15, 2023 | $6.1M |
| Nov 7, 2023 | Wingrove Theresa Officer | 19,517 0.01% of outstanding | $325k | Nov 7, 2023 | $5.7M |
| Nov 6, 2023 | Lentini Renee Officer | 219,545 0.08% of outstanding | $3.4M | Nov 6, 2023 | none |
| Nov 2, 2023 | Berkenblit Anna Officer | 109,435 0.04% of outstanding | $1.6M | Nov 2, 2023 | $22M |
| Oct 30, 2023 | Goldberg Mark Alan Director | 10,000 0.00% of outstanding | $151k | Oct 30, 2023 | none |
| Oct 16, 2023 | Wingrove Theresa Officer | 192,004 0.08% of outstanding | $2.8M | Sep 15, 2023 | $3.0M |
Transactions
The newest 50 of 241 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2024 | Tracey L McCain director | DDisposition to issuer Restricted Stock Unitderivative | -13,090 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Theresa Wingrove SVP OF REGULATORY AFFAIRS | DDisposition to issuer Common Stock | -21,039 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Isabel Kalofonos SVP & CHIEF COMMERCIAL OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -284,250 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Dean J Mitchell director | DDisposition to issuer Common Stock | -103,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Stuart A Arbuckle director | DDisposition to issuer Common Stock | -5,381 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Lauren White SVP, CFO AND PFO | DDisposition to issuer Stock Option (Right to Buy)derivative | +295,975 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Daniel Char SVP & CHIEF LEGAL OFFICER | DDisposition to issuer Common Stock | -1,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Richard John Wallace director | DDisposition to issuer Common Stock | -10,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Renee Lentini VP & PRIN ACCTG OFFICER | DDisposition to issuer Common Stock | -14,723 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Mark Alan Goldberg director | DDisposition to issuer Common Stock | -60,720 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Mark J Enyedy CHIEF EXECUTIVE OFFICER | DDisposition to issuer Common Stock | -584,397 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Stephen C McCluski director | DDisposition to issuer Restricted Stock Unitderivative | -13,090 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Michael Vasconcelles EVP R&D & MEDICAL AFFAIRS | DDisposition to issuer Common Stock | -1,327 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Kristine Peterson director | DDisposition to issuer Restricted Stock Unitderivative | -13,090 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Helen M. Thackray director | DDisposition to issuer Common Stock | -3,074 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER | DDisposition to issuer Common Stock | -73,274 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -150,610 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Richard John Wallace director | DDisposition to issuer Restricted Stock Unitderivative | -13,090 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Dean J Mitchell director | DDisposition to issuer Restricted Stock Unitderivative | -13,090 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Stephen C McCluski director | DDisposition to issuer Deferred Share Unitderivative | -105,458 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Tracey L McCain director | DDisposition to issuer Deferred Share Unitderivative | -50,303 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Stuart A Arbuckle director | DDisposition to issuer Restricted Stock Unitderivative | -13,090 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Isabel Kalofonos SVP & CHIEF COMMERCIAL OFFICER | DDisposition to issuer Restricted Stock Unitderivative | -47,375 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Michael Vasconcelles EVP R&D & MEDICAL AFFAIRS | DDisposition to issuer Stock Option (Right to Buy)derivative | -960,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Mark J Enyedy CHIEF EXECUTIVE OFFICER | DDisposition to issuer Restricted Stock Unitderivative | -102,466 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Lauren White SVP, CFO AND PFO | DDisposition to issuer Restricted Stock Unitderivative | +51,625 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Helen M. Thackray director | DDisposition to issuer Restricted Stock Unitderivative | -13,090 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Kristine Peterson director | DDisposition to issuer Deferred Share Unitderivative | -74,954 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Theresa Wingrove SVP OF REGULATORY AFFAIRS | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,871 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Renee Lentini VP & PRIN ACCTG OFFICER | DDisposition to issuer Restricted Stock Unitderivative | -39,370 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Daniel Char SVP & CHIEF LEGAL OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -400,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Mark Alan Goldberg director | DDisposition to issuer Restricted Stock Unitderivative | -13,090 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Mark Alan Goldberg director | DDisposition to issuer Deferred Share Unitderivative | -160,350 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -303,465 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Tracey L McCain director | DDisposition to issuer Stock Option (right to buy)derivative | -19,597 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Richard John Wallace director | DDisposition to issuer Deferred Share Unitderivative | -102,326 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Isabel Kalofonos SVP & CHIEF COMMERCIAL OFFICER | DDisposition to issuer Restricted Stock Unitderivative | -19,458 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Theresa Wingrove SVP OF REGULATORY AFFAIRS | DDisposition to issuer Stock Option (Right to Buy)derivative | -121,905 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Dean J Mitchell director | DDisposition to issuer Deferred Share Unitderivative | -142,667 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Stephen C McCluski director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Michael Vasconcelles EVP R&D & MEDICAL AFFAIRS | DDisposition to issuer Restricted Stock Unitderivative | -50,515 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Mark J Enyedy CHIEF EXECUTIVE OFFICER | DDisposition to issuer Restricted Stock Unitderivative | -140,357 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Kristine Peterson director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Helen M. Thackray director | DDisposition to issuer Deferred Share Unitderivative | -40,932 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Lauren White SVP, CFO AND PFO | DDisposition to issuer Restricted Stock Unitderivative | +19,519 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Renee Lentini VP & PRIN ACCTG OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,250 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Stuart A Arbuckle director | DDisposition to issuer Deferred Share Unitderivative | -63,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Daniel Char SVP & CHIEF LEGAL OFFICER | DDisposition to issuer Restricted Stock Unitderivative | -22,825 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Mark Alan Goldberg director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | Tracey L McCain director | DDisposition to issuer Stock Option (right to buy)derivative | -25,556 | - | - | 0 | Feb 12, 2024 |
50 of 241 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Stuart A Arbucklecoo, officer, director
- Daniel CharSVP & CHIEF LEGAL OFFICER
- Stacy Ann CoenSVP & CHIEF BUSINESS OFFICER
- Mark J EnyedyCHIEF EXECUTIVE OFFICER
- Mark Alan Goldbergdirector
- Isabel KalofonosSVP & CHIEF COMMERCIAL OFFICER
- Renee LentiniVP & PRIN ACCTG OFFICER
- Stephen C McCluskidirector
- Dean J Mitchelldirector
- Tracey L McCainofficer, director
- Kristine Petersondirector
- Helen M. Thackrayofficer, director
- Michael VasconcellesEVP R&D & MEDICAL AFFAIRS
- Richard John Wallacedirector
- Lauren WhiteSVP, CFO AND PFO
- Theresa WingroveSVP OF REGULATORY AFFAIRS
Questions about IMGN
Answered from the filings on this page, as of the latest one.
Are insiders buying IMGN?
No. In the last 90 days no insider at ImmunoGen, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade IMGN on the open market?
Stacy Ann Coen (SVP & CHIEF BUSINESS OFFICER) sold $134k of IMGN on Feb 5, 2024 and filed the Form 4 on Feb 6, 2024. InsiderTell scored 6 (weak), under a 10b5-1 plan, with 4 insiders on the same side within 14 days.
How many insiders file Form 4 at ImmunoGen, Inc.?
16 people have filed a Form 4 at ImmunoGen, Inc., among them Stuart A Arbuckle (COO and director), Daniel Char (SVP & CHIEF LEGAL OFFICER), Stacy Ann Coen (SVP & CHIEF BUSINESS OFFICER). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.